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1. Introduction 
Acetylcholine receptor (AChR) is a major auto- 
antigen involved in the neuromuscular disease 
myasthenia gravis (MG). Injection of experimental 
animals with purified AChR from electric fish leads 
to the elicitation of an immune response to this 
immunogen accompanied by a neuromuscular weak- 
ness, designated experimental autoimmune myasthenia 
gravis (EAMG) (reviewed [l-3]). Antibodies to 
AChR were shown to block the physiological activity 
of AChR [4-61 and to inhibit the binding of 
ar-bungarotoxin to the receptor [7]. However, it is 
still not known which parts or immunogenic 
determinants in the AChR molecule are responsible 
for its myasthenic activity and whether or not these 
overlap with sites involved in the physiological func- 
tion of the receptor. Detailed immunochemical 
analysis of AChR should shed light on these questions. 
We have demonstrated that a denatured prepara- 
tion of AChR (RCM-AChR, i.e., reduced and carboxy- 
methylated AChR) cross reacts partially with anti- 
AChR antibodies by reacting with antibodies directed 
against only part of the antigenic determinants present 
in the intact receptor [8]. Moreover, RCM-AChR by 
itself elicits an immune response which is not 
associated with any myasthenic symptoms, and is 
capable of specifically suppressing EAMG [9]. 
Analysis of the specificity of the immune response 
elicited by AChR and RCM-AChR led us to propose 
that the denaturation of AChR destroys some 
structural antigenic determinants which are important 
for the induction of EAMG, and which may be 
located close to the toxin binding site [8,9]. AChR 
elicits antibodies against both myasthenic deter- 
minants in the AChR molecule which are involved in 
the disease and other antigenic determinants which 
are not involved in the disease. RCM-AChR cross 
reacts only with antibodies of the latter specificity 
and by itself elicits an immune response only to 
determinants other than the myasthenic ones. 
Here we describe the fractionation of two antibody 
populations different in their immunological and 
physiological specificity from rabbit anti-AChR 
serum. The fractionation was achieved by using an 
immunoadsorbent of RCM-AChR bound to Sepharose. 
Both the adsorbed and unadsorbed subpopulations of 
antibodies bind to iritact AChR, whereas only the 
subpopulation which does not bind to RCM-AChR 
blocks the in vitro binding of cw-bungarotoxin to 
AChR. 
2. Materials and methods 
AChR was isolated from the electric organ of 
Torpedo californica (Pacific Bio-Marine, Venice, 
CA) and was purified as in [7]. Reduced carboxy- 
methylated AChR (RCM-AChR) was prepared by 
reduction and carboxymethylation of AChR in 6 M 
guanidine-HCl [8], cz-bungarotoxin (ol-Bgt) was 
prepared according to [lo]. Iodination with 12’1 of 
these three proteins was performed by the 
chloramine-T method [ 1 I]. 
2.1. Preparation of RCM-AChR-Sepharose immuno- 
adsorbent and fractionation of antibodies 
RCM-AChR was bound to Sepharose 2B which 
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had been activated with CNBr [12]. CNBr-activated 
Sepharose (10 g) was added to a solution of RCM- 
AChR (8 mg) in 0.1 M NaHCOa (25 ml). The mixture 
was kept overnight at 4°C with gentle stirring and was 
then washed with PBS. The RC~-AChR-~pharose 
iinmunoadsorbent was packed into a column and 
anti-AChR serum (2 ml) was chromatographed through 
it at room temperature. The unadsorbed antibody 
fraction which came through the column was 
designated effluent. Antibodies which were immuno- 
specifically adsorbed to the column were eluted with 
0.2 M NH_+OH and dialyzed against several changes of 
PBS (eluate). Both antibody fractions were adjusted 
with PBS to 10 times the original volume of the 
serum applied to the column. 
2.2, immunization 
Rabbits (2-3 kg) were injected in the footpads 
and intradermally in 3-4 spots, each with 100 pg 
AChR emulsified with complete Freund’s adjuvant . 
The animals were bled when myasthenic symptoms 
were observed (-30 days following immunization). 
2.3. imrn~n~~ogi~al assays 
For radioimmunoassay, the anti-AChR serum, or 
fractionated antibodies (0.1 ml in 10% normal rabbit 
serum) was incubated with the radioactive antigen 
(‘251-labelled AChR, 1251-labelled RCM-AChR or 
‘251-labelled a-Bgt-AChR) for 30 min at 37°C. Goat- 
anti rabbit immunoglobulin serum (0.1 ml) was added 
and the tubes were incubated for an additional 30 min 
at 37°C. The centrifuged precipitates were washed 
twice and counted in an autogamma scintillation 
counter. For inhibition experiments the antiserum 
(at a dilution that binds 20-40% of the radioactive 
antigen) was preincubated with different amounts of 
inhibitor for 30 min at 37’C and the assay was 
continued as above for binding. 
2.4. Eff~ct~fa~tib~dieson the bindj~g~f ‘2s1-labelled 
~-bunga$~t~xi~ to AChR 
The assay of ‘251-labelled cu-Bgt binding to AChR 
was performed as in [7]. The inhibition of the binding 
of toxin to AChR by specific antisera was measured 
by preincubation of AChR with increasing amounts 
of serum for 30 min at 37*C before the addition of 
125 I-labelled o-Bgt . The degree of toxin-binding was 
determined relative to the binding obtained when 
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‘251-labelled cr-Bgt was reacted with AChR before the 
incubation with the serum. 
3. Results 
3.1. Fra~t~~~ation and immunol~~ea~ anaIysis of 
two different an ti-AChR antibody populations 
Antibody fractionation was performed on sera 
from rabbits which were immunized with AChR 
and had clinical signs of EAMG. Serum fractionation 
was performed as in section 2. Direct binding of the 
fractionated antibodies with labeled antigens was 
determined by a radioimmunoassay. As can be seen 
in figSA ~fractionated anti-AChR serum binds 
to intact AChR (‘251-labeled AChR or ‘251-labeled 
o-Bgt-AChR) as well as to denatured receptor 
(‘*‘I-labeled RCM-AChR). After this serum was 
chromatographed on RCM-AChR-Sepharose, the 
effluent does not bind RCM-AChR anymore, but 
binds to intact AChR (8g.lB). In contrast, the 
second antibody fraction eluted from the adsorbent 
(eluate) binds to both AChR and RCM-AChR (fig.1 C). 
A similar pattern of specificity was obtained in 
experiments in which inhibition of the binding of 
1251-labeled AChR to the different antibody fractions 
was studied. RCM-AChR is a weaker inhibitor than 
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Fig.1. Binding of ‘251-labeled AChR (8 -•), ‘ZsElabeied 
RCM-AChR (o- - - -0) and ‘251-labeled cu-Bgt-AChR 
(a- . +) To: (A), unfractionated anti-AChR serum;(B) 
effluent serum which did not bind to RCM-AChR-Sepharose; 
(C) eluted antibody fraction. The first dilution for the 
antibody samples (10-r) is: for (A), a l/10 dilution of the 
unfractionated serum; for(B) and (C), the respective antibody 
fraction after its total volume has been adjusted to IO-times 
the original volume of the serum applied to the column (see 
section 2). 
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Fig.2. Inhibition of the binding of ‘asI-labeled AChR to: (A) 
unfractionated anti-AChR serum; (B) effluent serum; (C) 
eluted antibody fraction, by unlabelled AChR (- ) and 
RCM-AChR (-----). 
AChR of the binding of 1251-labeled AChR to 
unfractionated anti-AChR and inhibits only part of 
the binding (fig.ZA) [8,9]. However, there is no 
inhibition at all by RCM-AChR of the binding of 
1251-labeled AChR to the effluent serum whereas 
AChR is a good inhibitor (fig.2B). There is no dif- 
ference in the extent of inhibition by AChR and 
RCM-AChR of the binding of ‘251-labeled AChR to 
the eluted antibodies (fig.2C). This latter population 
of antibodies (eluate) is the one which is common 
to the intact and denatured receptor, whereas the 
subpopulation of antibodies in the effluent 
recognizes only the intact receptor and does not 
cross react with the denatured receptor. 
3.2. Effect of the fractionated antibodies on the 
binding of bungarotoxin to AChR 
Antibodies to AChR were shown to block the 
physiological activity of AChR and this reaction is 
possibly associated with the pathogenesis of auto- 
immune myasthenia gravis [4-61. These antibodies 
also inhibit the in vitro binding of cu-bungarotoxin 
to AChR [7,8,13]. 
Acetylcholine receptor is a multisubunit high 
molecular weight protein [7,14-161 containing a 
variety of immunopotent determinants. Thus, 
immunization with such an immunogen leads to the 
production of antibodies of heterogeneous antigenic 
specificities. It is likely that antibodies of only 
limited defined specificities are involved in the 
pathogenesis of EAMG. Zurn and Fulpius [I 31 have 
shown that in an AChR-immunized rabbit there was a 
relative increase in the level of antibodies which block 
toxin binding to the receptor concomitantly with the 
onset of EAMG, and implied that this antibody sub- 
population might play a role in the appearance of the 
paralysis observed in this disease. 
Comparison of the effect of anti-AChR serum Here we have fractionated two antibody sub- 
with that of the fractionated antibodies, on the populations from sera of AChR-injected rabbits, by. 
binding of ‘2SI-labeled cu-Bgt o AChR shows that the using a RCM-AChR-Sepharose immunoadsorbent .
effluent antibodies which do not bind to RCM-AChR Antibodies which were not adsorbed by the immuno- 
are those which block the binding of a-bungarotoxin adsorbent (effluent) were directed to determinants 
to AChR (fig.3). which are present only on the intact AChR (fig.l,2). 
1 I I I 
I I I 
ii35 fZ% W 
L 
IO 
Antlbody (dtlutton) 
Fig.3. Inhibition of the binding of ‘251-labeled a-Bgt to AChR 
by: unfractionated anti-AChR serum, (o -0); effluent 
serum (0 -0); eluted antibody fraction (A ---_A), and 
normal rabbit serum (----). 
4. Discussion 
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Only this antibody population blocks toxin binding 
to the receptor (fig.3) and it is possible that it 
represents the antibodies which are relevant in 
causing the neuromuscular damage in animals with 
myasthenia gravis [13]. If so it may be possible to 
transfer EAMG to normal rabbits by this antibody 
subpopulation. The antibody subpopulation which is 
bound to the immunoadsorbent, binds equally AChR 
and RCM-AChR (fig.l,2) and does not block the 
binding of toxin to the receptor (fig.3). Such a 
specificity was observed in rabbits immunized with 
RCM-AChR [8] and was predominant also in rabbits 
in which EAMG was prevented or reversed by RCM- 
AChR injection [9]. These antibodies are probably 
directed exclusively against sequentional antigenic 
determinants [ 171 in AChR. Transfer of this sub- 
population of antibodies to myasthenic rabbits may 
lead to suppression of the disease. We have not 
succeeded in transferring myasthenia to rabbits by 
unfractionated rabbit anti-AChR serum (Tarrab- 
Hazdai and SF., unpublished data), but this may 
result from the fact that in unfractionated serum 
antibodies of physiologically opposite functions 
(blocking and non-blocking) are present. 
Further immunochemical analysis of AChR, 
isolation of the different antigenic determinants and 
the respective specific antibodies may help for a 
detailed structural analysis of AChR and for 
characterizing the exact specificity of antibody 
involved in the pathogenesis of both experimental 
and human myasthenia. 
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